Peptide Research Profile

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA Type-c — Mitochondria-Derived Peptide

Evidence Grade: Preclinical · Discovered 2015 · Extremely Early Stage

A 16-amino-acid peptide encoded in the mitochondrial genome (within the 12S rRNA gene), discovered in 2015 by Changhan David Lee’s laboratory at USC. MOTS-c is classified as a mitochondria-derived peptide (MDP) — the first demonstrated to regulate nuclear gene expression, making it a mitochondria-to-nucleus retrograde signaling molecule. It activates AMPK, enhances glucose utilization, and has been described as an “exercise mimetic” in rodent models. Despite enormous hype, MOTS-c is at the very earliest stage of research with zero human clinical trial data published as of 2025.

Medical Disclaimer: This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MOTS-c was discovered in 2015 and is extremely early stage. ALL data is preclinical (rodent/cell culture). Zero human trials exist. Always consult a qualified healthcare professional before using any peptide compound. PAA does not sell, distribute, or recommend the purchase of any research compound.

At a Glance Mechanism of Action Delivery Routes Dosing Benefits & Side Effects Key Studies Research Gaps References

Quick Reference

At a glance

Classification

Mitochondria-Derived Peptide

16 amino acids — encoded by mitochondrial DNA (12S rRNA gene)

Discovered

2015

Lee C et al., Cell Metabolism — USC Leonard Davis School of Gerontology

Evidence Level

Preclinical Only

Rodent models + cell culture • Zero human clinical trials

Key Pathway

AMPK Activation

AICAR-like AMPK activator • Folate/methionine cycle modulation • Nuclear gene regulation

Pharmacology

Mechanism of action

MOTS-c is remarkable because it is one of very few peptides known to be encoded by mitochondrial DNA yet act on the nucleus — a retrograde signaling molecule that challenges the traditional view of mitochondria as passive organelles. Its mechanism centers on AMPK activation through depletion of the folate/methionine cycle, making it a metabolic stress-response peptide that shifts cellular energetics toward glucose utilization and away from fat storage. The “exercise mimetic” label reflects MOTS-c’s ability to activate the same AMPK-mediated pathways that exercise engages.

Mitochondrial Origin & Endogenous Production

MOTS-c is translated from a short open reading frame (sORF) within the 12S rRNA gene of mitochondrial DNA. This is unusual — rRNA genes were thought to encode only structural RNA, not proteins. Endogenous MOTS-c is detectable in plasma, skeletal muscle, and multiple tissues. Circulating levels decline with age and are reduced in insulin-resistant states. Exercise transiently increases MOTS-c levels, consistent with its proposed role as a metabolic stress signal.

Mitochondrial sORF biology: The 12S rRNA gene contains a previously unrecognized short open reading frame that encodes the 16-amino-acid MOTS-c sequence (MRWQEMGYIFYPRKLR). This sORF is conserved across species, suggesting functional importance maintained by natural selection. MOTS-c is one of several mitochondria-derived peptides (MDPs) including humanin and SHLPs (small humanin-like peptides). How MOTS-c is exported from mitochondria to the cytosol and then to the nucleus or extracellularly is incompletely understood but may involve the mitochondrial-derived vesicle (MDV) pathway or direct translocation through the outer mitochondrial membrane.

Folate Cycle Disruption & 5-AICAR Accumulation

MOTS-c inhibits the folate/methionine one-carbon cycle by reducing the activity of methylenetetrahydrofolate dehydrogenase (MTHFD2). This disruption leads to accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an endogenous intermediate in de novo purine biosynthesis. AICAR is a potent AMPK activator. This is the primary mechanism by which MOTS-c activates AMPK — it doesn’t bind AMPK directly but instead creates the metabolic conditions that activate it.

AICAR/AMPK connection: AICAR is phosphorylated to ZMP (the monophosphate form of AICAR), which binds the γ-subunit of AMPK, mimicking AMP and activating the kinase. This is the same mechanism exploited by the pharmaceutical AICAR (acadesine), which was investigated as an exercise mimetic and anti-ischemic agent. By inhibiting the folate cycle upstream of purine synthesis, MOTS-c causes endogenous AICAR to accumulate rather than being consumed in purine biosynthesis. This is an elegant indirect mechanism — rather than directly targeting AMPK, MOTS-c manipulates cellular metabolism to produce the endogenous AMPK activator.

AMPK Activation & Metabolic Reprogramming

Activated AMPK is the master metabolic switch that shifts cellular energetics from anabolic (storage) to catabolic (utilization). AMPK activation by MOTS-c increases glucose uptake (GLUT4 translocation), enhances fatty acid oxidation (ACC phosphorylation/inhibition), suppresses mTORC1 (reducing lipogenesis and protein synthesis), and activates PGC-1α (mitochondrial biogenesis). The net effect is improved glucose disposal, enhanced insulin sensitivity, and increased energy expenditure.

AMPK downstream targets: AMPK phosphorylates and inactivates ACC1/ACC2 (inhibiting de novo lipogenesis and activating CPT1-mediated fatty acid import into mitochondria). It phosphorylates TBC1D1/TBC1D4, promoting GLUT4 vesicle translocation to the plasma membrane (insulin-independent glucose uptake). It phosphorylates TSC2, activating the tuberin/hamartin complex that inhibits mTORC1 (reducing anabolic processes). It phosphorylates ULK1, initiating autophagy (cellular recycling). These combined actions explain why AMPK activation mimics many metabolic benefits of exercise and caloric restriction.

Nuclear Translocation & Gene Regulation

MOTS-c translocates to the nucleus under metabolic stress conditions (glucose deprivation, oxidative stress), where it directly regulates gene expression by interacting with nuclear transcription factors. This mitochondria-to-nucleus retrograde signaling represents a novel regulatory axis. In the nucleus, MOTS-c modulates genes involved in antioxidant defense (NRF2 pathway), inflammation (NF-κB suppression), and glucose metabolism.

Nuclear mechanism: Under basal conditions, MOTS-c is primarily cytosolic. Metabolic stress triggers its nuclear import, potentially via interaction with importin-β transport receptors. In the nucleus, MOTS-c has been shown to interact with ARE (antioxidant response element) regions in promoters of NRF2-target genes, enhancing antioxidant gene expression (HO-1, NQO1, GCLM). It also suppresses NF-κB nuclear activity, reducing inflammatory gene expression (TNF-α, IL-6, IL-1β). The nuclear translocation mechanism and binding partners are still being characterized — this is an area of very active research.

Exercise Mimetic Effects in Rodent Models

In high-fat-diet (HFD) mice, MOTS-c administration (5 mg/kg/day IP) prevented obesity, improved glucose tolerance, and increased insulin sensitivity. In aged mice, MOTS-c improved physical performance (treadmill endurance). In skeletal muscle-specific analyses, MOTS-c increased mitochondrial content and oxidative fiber proportion — changes typically seen with exercise training. These findings generated the “exercise mimetic” description that has driven community interest.

Key rodent data: Lee et al. (2015) showed that 7 days of MOTS-c (5 mg/kg IP) in HFD mice reduced body weight, decreased fat mass, and improved glucose tolerance test (GTT) to levels comparable to chow-fed controls. Reynolds et al. (2021) demonstrated that MOTS-c administration in aged mice (22 months, equivalent to ~70 human years) improved treadmill running time by ~30% and improved grip strength. The exercise-like gene expression signature in skeletal muscle included upregulation of PGC-1α, cytochrome c, and citrate synthase. Critically, all of these studies used intraperitoneal injection at doses (5 mg/kg) that translate to very large human doses, and no human dose-response or PK data exists.

Administration

Delivery routes

Subcutaneous Injection

Community Use — No Human PK Data

The route used by community and self-experimenters. Reconstituted from lyophilized powder. No human pharmacokinetic data exists for SC MOTS-c. Bioavailability, optimal dose, and dose-response are unknown for this route. All published rodent data uses intraperitoneal (IP) injection, which is not equivalent to subcutaneous.

Intraperitoneal (Rodent)

Research Only — Published Route

All published rodent studies used IP injection at 5–15 mg/kg. IP delivers directly to the peritoneal cavity with rapid systemic absorption. This route is standard in rodent research but not used in humans. The IP doses used (5 mg/kg = ~350 mg for a 70 kg human) are dramatically higher than community SC doses (5–10 mg).

Oral

Likely Not Viable

A 16-amino-acid peptide would face significant gastrointestinal degradation. No oral MOTS-c data exists. However, some very small peptides can achieve limited oral bioavailability — MOTS-c’s size (1,765 Da) is in a borderline range. Until oral PK studies are conducted, this route cannot be assessed.

Intravenous

Untested

No published IV administration data. If human clinical trials are eventually conducted, IV would likely be studied alongside SC for PK comparison. For a small peptide, IV would provide the most reliable plasma levels but is impractical for repeated self-administration.

Protocols

Dosing reference

No established human dosing exists for MOTS-c. All published dose data is from rodent IP injection. Community dosing protocols are entirely extrapolated and should be viewed with extreme caution.

Context	Dose	Frequency	Source
Rodent obesity prevention	5 mg/kg/day IP ~350 mg/day human equivalent (NOT directly translatable)	Daily for 7–14 days	Lee et al., Cell Metabolism 2015
Rodent aging / performance	5–15 mg/kg IP Varied by study	Daily or 3x/week	Reynolds et al., 2021
Community SC protocol	5–10 mg SC No human PK supports this dose	Daily or 3–5x/week for 4–8 weeks	Anecdotal / community — zero clinical evidence
No established human dose	— Human PK, bioavailability, and dose-response completely unknown	—	No human data

Important: There is NO established human dose for MOTS-c. The rodent doses (5 mg/kg IP) translate to massive human doses that are not practical or validated. Community SC doses (5–10 mg) are orders of magnitude lower than rodent-equivalent doses and are chosen for cost reasons, not pharmacological rationale. Whether 5–10 mg SC achieves any biologically meaningful plasma or tissue concentration in humans is completely unknown. Self-administering MOTS-c is experimenting in the truest sense of the word.

Outcomes

Benefits & side effects

Reported Benefits

Metabolic Improvement in Rodents

Prevented diet-induced obesity and insulin resistance in high-fat-diet mouse models. Improved glucose tolerance, reduced fat mass, and increased energy expenditure. These are robust and replicated findings across multiple rodent studies from the Lee laboratory and others.

Rodent IP studies • n=8–12 per group • No human data

Exercise Mimetic Properties

Improved treadmill endurance and grip strength in aged mice. Increased mitochondrial content and oxidative fiber proportion in skeletal muscle. Activated the same AMPK/PGC-1α pathways engaged by exercise training. These findings are the source of the “exercise in a bottle” description.

Rodent models only • Reynolds et al., 2021

Anti-Inflammatory & Antioxidant

MOTS-c suppresses NF-κB-mediated inflammatory gene expression and activates NRF2-dependent antioxidant defenses. In rodent models of inflammatory challenge, MOTS-c reduced circulating IL-6, TNF-α, and oxidative stress markers.

Rodent + cell culture • No human inflammation data

Aging Biology Relevance

Endogenous MOTS-c levels decline with age. MOTS-c administration in aged mice improved healthspan markers. The mitochondrial origin and age-related decline suggest MOTS-c may be a genuine longevity-related peptide, though this is speculative based on current evidence.

Correlative + rodent intervention • Longevity claims are premature

Adverse Effects & Risks

Unknown Safety Profile

No human safety data exists. Zero adverse events have been documented because zero human trials have been conducted. The absence of reported side effects reflects absence of study, not absence of risk.

Complete absence of human data

AMPK Overactivation Concern

Chronic AMPK activation can be detrimental: it suppresses mTORC1 (reducing muscle protein synthesis), can impair cardiac hypertrophic responses (important for exercise-induced cardiac adaptation), and may paradoxically worsen some neurodegenerative conditions. Metformin (another AMPK activator) has been shown to blunt muscle hypertrophy gains from resistance exercise.

Pharmacological class concern • Metformin/exercise interference literature

Folate Cycle Disruption

MOTS-c’s mechanism involves inhibiting the folate/methionine cycle. Chronic disruption of folate metabolism could theoretically impair DNA synthesis, methylation reactions, and nucleotide availability. This is particularly concerning for rapidly dividing cells (bone marrow, gut epithelium) and during pregnancy (folate deficiency causes neural tube defects).

Mechanism-based theoretical risk

Unknown Interaction with Exercise

If MOTS-c activates the same AMPK pathway as exercise, does co-administration with exercise produce additive benefit, redundancy, or interference? Metformin (AMPK activator) blunts some exercise adaptations. MOTS-c could theoretically do the same. This question is unanswered.

Theoretical • Based on metformin/exercise interference data

Peptide Quality & Identity Concerns

MOTS-c is a novel, recently discovered peptide. Analytical standards for verifying its identity and purity are not well-established in the commercial peptide market. The risk of receiving degraded, mislabeled, or impure product from gray-market sources is higher than for well-established peptides.

Supply chain concern • Quality assurance lacking

Evidence Base

Key studies

Discovery Paper — Cell Culture + Rodent

The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis

Lee C et al. • Cell Metabolism • 2015 • Cell culture + mouse models

Design & Findings

Identified MOTS-c as a 16-amino-acid peptide encoded by mitochondrial DNA. Demonstrated it activates AMPK via folate cycle inhibition/AICAR accumulation. In HFD mice, MOTS-c (5 mg/kg/day IP) prevented obesity and insulin resistance. Circulating MOTS-c was detectable in human plasma.

Significance

The foundational discovery paper. Established MOTS-c as the first mitochondria-encoded peptide demonstrated to regulate systemic metabolism. Published in a high-impact journal (Cell Metabolism) and has generated enormous research interest.

Limitations

Discovery paper focused on mechanism, not therapeutic development. Rodent doses are not translatable to human SC dosing. No human intervention data. Single-laboratory findings at the time of publication. The IP route used in mice produces different PK than SC.

View on PubMed

Preclinical — Aging

MOTS-c Improves Physical Function in Aged Mice

Reynolds et al. • Aging Cell • 2021 • Mouse Model

Design & Findings

MOTS-c administration (15 mg/kg IP, 3x/week for 2 weeks) in 22-month-old mice improved treadmill endurance, grip strength, and gait speed compared to vehicle-treated aged controls. Skeletal muscle showed increased mitochondrial content and AMPK activation. Physical function metrics approached (but did not reach) those of young adult mice.

Significance

First evidence of MOTS-c improving physical function in aged animals. Provides preclinical support for the anti-aging/healthspan narrative. The aged mouse model (22 months ≈ 70 human years) is translationally relevant.

Limitations

Mouse model only. Short treatment duration (2 weeks). Small sample sizes. IP injection route. Doses (15 mg/kg) translate to >1 gram daily in humans. No long-term follow-up. Single laboratory.

View on PubMed

Translational — Human Correlative

MOTS-c and Physical Activity in Middle-Aged Adults

D’Souza RF et al. • Various journals • 2020–2023 • Human observational

Design & Findings

Several observational studies measured endogenous MOTS-c levels in human plasma and skeletal muscle. Findings: MOTS-c levels are higher in physically active individuals, decline with age, are lower in insulin-resistant subjects, and increase acutely after exercise. These correlations support MOTS-c as an exercise-responsive metabolic signal in humans.

Significance

Validates that MOTS-c biology is relevant in humans, not just rodents. The exercise-responsiveness and age-related decline provide a rationale for therapeutic investigation. However, correlation does not prove causation.

Limitations

Observational/correlative only — no intervention. Small sample sizes (n=20–50). Cross-sectional designs cannot establish causation. Plasma MOTS-c levels may not reflect tissue concentrations. No link to clinical outcomes.

View on PubMed

Open Questions

Research gaps

Zero Human Clinical Trials

As of 2025, no registered clinical trial of exogenous MOTS-c administration in humans has been completed or published. The entire evidence base is rodent and cell culture. This is the most fundamental gap — MOTS-c’s effects in humans are entirely unknown. Many promising rodent findings fail to translate.

No Human PK Data

Subcutaneous bioavailability, plasma half-life, tissue distribution, dose-response, and metabolic clearance of exogenous MOTS-c in humans are completely uncharacterized. Community dosing (5–10 mg SC) is based on nothing more than cost constraints and anecdote.

Massive Dose Translation Gap

Rodent effective doses (5–15 mg/kg IP) translate to 350–1,050 mg/day for a 70 kg human via a more bioavailable route. Community doses of 5–10 mg SC are 35–200x lower than allometric scaling would suggest. Whether these community doses achieve any biologically meaningful effect is unknown.

Single-Lab Dependency

The majority of MOTS-c research originates from Changhan David Lee’s laboratory at USC. While other groups have published correlative studies, the core intervention findings (obesity prevention, exercise mimicry, aging improvement) are from a single research group. Independent replication of the key therapeutic claims is limited.

Exercise Interaction Unknown

Most community users of MOTS-c also exercise. Whether MOTS-c enhances, is redundant with, or interferes with exercise adaptations is completely unknown. The metformin precedent (AMPK activator that blunts some exercise responses) raises a legitimate concern that has not been addressed.

Long-Term Folate Cycle Effects

MOTS-c’s mechanism involves disrupting the folate/methionine cycle. Chronic disruption of this pathway could impair methylation reactions, nucleotide synthesis, and epigenetic regulation. No long-term safety data exists for any AMPK activator that works through this specific mechanism.

Citations

References & further reading

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed

2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed

3. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression. Nat Commun. 2018;9(1):3073. PubMed

4. D’Souza RF, Woodhead JST, Zeng N, et al. Circulatory exerkines and MOTS-c during a bout of acute exercise. J Appl Physiol. 2020;129(5):1258-1267. PubMed

5. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016;100:182-187. PubMed

All MOTS-c on PubMed → ← Back to Research Library